Coeliac disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• JAK 0
• TNF 0
• NLRP3 0
• NRF2 0
• STAT3 0
• TLR4 0
• BDNF 0
• BTK 0
• FOXP3 0
• G6PD 0
• IL-15 0
• IL-6 0
• mTOR 0
• TP53 0

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIGMS · F32

  Understanding the Roles of Glycosylated RNA Species in Homeostasis and Human Disease

  Rice University· Houston, United States· US$76,300 awarded in fiscal year 2026· until Sept 2029

• NIH NIDDK · R01

  Longitudinal analysis of T-B cell interactions and clonal dynamics to identify immune programs controlling tissue damage and healing in celiac disease

  University of Chicago· Chicago, United States· US$819,998 awarded in fiscal year 2026· until Jun 2030

• NIH NIDDK · DP1

  Redefining the Biogeography and Function of Food Proteins in Human Health and Disease

  Boston Children's Hospital· Boston, United States· US$831,433 awarded in fiscal year 2026· until Jun 2031

• NIH NIDDK · R01

  The role of microbiota specific T cells in Inflammatory Bowel Disease

  Icahn School of Medicine at Mount Sinai· New York, United States· US$726,142 awarded in fiscal year 2026· until May 2031

• NIH NIGMS · K99

  Harnessing Hydrophobic Interactions for Photocaging and Photoproximity Labeling

  University of California, San Diego· La Jolla, United States· US$125,000 awarded in fiscal year 2026· until Jul 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Exploring the dynamics of the gastrointestinal tract using shed cell and spatial transcriptomics (GI-DYNAMICS)

  Weizmann Institute of Science· Rehovot, Israel· EU contribution €2,500,000· until Nov 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular chirality tools for the study of Gluten Immunogenic Peptides and Celiac Disease: Novel therapeutic and diagnostic approaches. (GLUCHIRAL)

  Universidad de Sevilla· Sevilla, Spain· EU contribution €226,441· until Feb 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Tracking gluten immunoreactive peptides from the grain to the gut and beyond (GLUTENOMICS)

  Leibniz-Institut Fuer Lebensmittel-Systembiologie An Der Technischen Universitaet Muenchen· Freising, Germany· EU contribution €1,499,988· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology (geneTIGA)

  Charite - Universitaetsmedizin Berlin· Berlin, Germany· EU contribution €6,393,734· until Dec 2026· 8 countries

  The disease is named only in the funder's project summary, not in the title.

9 of 74 running projects, newest first. Listed amounts together: US$42.0m + €10.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Organoids 2
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 2
• Gene Expression Profiling 3
• Proteomics 8
• Metabolomics 4
• Mass Spectrometry 2
• Flow Cytometry 3
• Immunohistochemistry 7
• Magnetic Resonance Imaging 4
• Machine Learning 4
• Deep Learning 3
• Cohort Studies 25
• Genome-Wide Association Study 14

• Immunoproteomic Profiling of Autoantibodies and Antibodies against Infectious Agents in Autoimmune Diseases.

  J Proteome Res, Sept 2026

• Proteomic Analysis Highlights Peculiar Protein and Phosphoprotein Profiles in Dermal Fibroblasts from Celiac Disease Patients.

  Int J Mol Sci, Apr 2026

• Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.

  BMC Med, Apr 2026

• Discovery and screening of thermostable signature peptides for robust quantification of wheat allergens in processed foods.

  Food Chem, Feb 2026

• Unsupervised learning reveals novel disease-associated proteins in high-dimensional human proteomic data.

  Sci Rep, Feb 2026

• Proteomics Analysis of Celiac Disease-Active Peptides in Food Products with Partially Hydrolyzed Gluten.

  J Agric Food Chem, Jan 2026

• A set of serum proteomic biomarkers differentiates celiac children from age and human leukocyte antigen-matched healthy controls.

  J Pediatr Gastroenterol Nutr, Nov 2025

• Celiac Disease: Conventional and Novel Biomarkers.

  Gastroenterol Clin North Am, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.